跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
駱 雨利
教授
藥理學研究所
電話
02-28267000#6451
電子郵件
yulilo
nycu.edu
tw
網站
https://yulilo.web.nycu.edu.tw/
h-index
h10-index
h5-index
1998
引文
28
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
700
引文
15
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
177
引文
6
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1995 …
2024
每年研究成果
概覽
指紋
網路
研究成果
(58)
類似的個人檔案
(6)
指紋
查看啟用 Yu-Li Lo 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Epirubicin
94%
Nanoparticle
61%
Multidrug Resistance
57%
Liposome
40%
Epidermal Growth Factor Receptor
38%
Neoplasm
31%
microRNA
29%
Afatinib
22%
Cytotoxicity
22%
Malignant Neoplasm
21%
Acrolein
19%
Polyethylene Glycol
19%
Colorectal Carcinoma
17%
Messenger RNA
16%
Tumor Microenvironment
15%
Head and Neck Cancer
15%
Macrogol
14%
Reactive Oxygen Metabolite
14%
P-Glycoprotein
12%
Effusion
12%
Anticarcinogen
12%
Sustained Release
11%
Poloxamer
11%
Multidrug Resistance Protein 1
11%
Solid Lipid Nanoparticle
11%
Multidrug Resistance-Associated Protein 2
11%
Multidrug Resistance Associated Protein 1
10%
Polypeptide Antibiotic Agent
10%
Cancer Inhibition
10%
Colon Adenocarcinoma
10%
Polyacrylic Acid
10%
Neurotoxicity
10%
Nervous System Inflammation
10%
Uterine Cervix Cancer
9%
Tumor Growth
9%
Immunologic Adjuvant
9%
Pancreas Cancer
9%
Tilapia
9%
Pilocarpine
9%
Chitosan
9%
Antisense Oligonucleotide
9%
Antiinflammatory Activity
9%
Dopamine Receptor Stimulating Agent
9%
Neuroprotective Agent
9%
Blood-Brain Barrier
9%
Docetaxel
9%
Triple Negative Breast Cancer
9%
Tween 80
9%
Catenin
8%
Hepcidin
8%
Keyphrases
Epirubicin
100%
Caco-2 Cells
40%
Multidrug Resistance
35%
Liposomes
30%
Nanoparticles
29%
MicroRNA
29%
Afatinib
24%
Apoptosis
19%
Acrolein
19%
Cytotoxicity
18%
Induced Apoptosis
17%
Multidrug Resistance Reversal
16%
PH-sensitive
16%
Anticancer Drugs
15%
Head-and-neck Cancer
15%
Acrylic Acid
14%
Cas9 Protein
14%
Catenin
14%
Targeting Peptide
14%
Phosphatidylglycerol
14%
Multidrug Resistance Protein 1 (MDR1)
14%
Fourier Transform Infrared Spectroscopy (FT-IR)
13%
Pluronic
13%
Superoxide Dismutase
13%
Liposomal
13%
P-glycoprotein (P-gp)
12%
Differential Scanning Calorimetry
12%
Nanoformulation
11%
HeLa Cells
11%
Co-treatment
11%
PEGylated Liposomes
11%
Targeted Nanoparticles
11%
Multidrug Resistance-associated Protein 2 (MRP2)
11%
Rat Intestine
11%
Reactive Oxygen Species Production
11%
Everted Gut Sac
11%
Sustained Release
10%
Epidermal Growth Factor Receptor
10%
Intestinal Epithelial Cells
10%
Interleukin-4 (IL-4)
10%
Tumor Microenvironment
10%
Neurotoxicity
10%
Peptide-modified
10%
Antimicrobial Peptides
10%
Polyethylene Glycol
10%
B-cell Lymphoma 2 (Bcl-2)
10%
Neuroinflammation
10%
Liposomal Formulation
9%
MicroRNA-125b
9%
CRMP2
9%
